Patent EP0528312A2 successfully refreshed from Google Patents.
EP0528312A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Cyclic peptides and use thereof
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1992-08-08
•
Granted: —
•
Expires: 2012-08-08
Abstract
Abstract Disclosed are (1) a cyclic hexapeptide represented by formula [I] or a salt thereof: <CHEM> wherein X and Y each represent alpha -amino acid residues, A represents a D-acidic- alpha -amino acid residue, B represents a neutral- alpha -amino acid residue, C represents an L- alpha -amino acid residue and D represents a D- alpha -amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventors
- 👤 Mitsuhiro Wakimasu
- 👤 Takashi Kikuchi
- 👤 Akira Kawada
- 👤 Hideo Shirahuji
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 11:20
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57536; A; A61; A61P; A61P11/00; A61P13/00; A61P13/02; A61P15/00; A61P29/00; A61P3/00; A61P3/06; A61P35/00; A61P9/00; A61P9/12; C07K7/00; C07K7/64; A61K; A61K38/00; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
66 words
A compound comprising a cyclic peptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; wherein hydroxy, thiol, amino, imino and carboxyl groups can be substituted or unsubstituted.
Claim 2
Dependent Claim
66 words
A compound comprising a cyclic peptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; wherein hydroxy, thiol, amino, imino and carboxyl groups can be substituted or unsubstituted.
Claim 3
Dependent Claim
10 words
The compound according to claim 1, wherein X has L-configuration.
Claim 4
Dependent Claim
10 words
The compound according to claim 1, wherein Y has L-configuration.
Claim 5
Dependent Claim
24 words
The compound according to claim 4, wherein A is selected from the group consisting of D-glutamic acid, D-aspartic acid, D-cysteic acid and D-,8-(5-tetrazolyl)alanine residue.
Claim 6
Dependent Claim
10 words
The compound according to claim 1, wherein B has D-configuration.
Claim 7
Dependent Claim
27 words
The compound according to claim 1, wherein B is selected from the group consisting of 1-aminocyclopropane-1-carboxylic acid, 1-aminocyclobutane-1-carboxylic acid, 1-aminocyclopentane-1-carboxylic acid, 1-aminocyclohexane-1-carboxylic acid and 1-aminocycloheptane-1-carboxylic acid residue.
Claim 8
Dependent Claim
30 words
The compound according to claim 6, wherein B is selected from the group consisting of D-leucine, D-alloisoleucine, D-tertiaryleucine, D-gammamethylleucine, D-phenylglycine, D-2-thienylglycine, D-3-thienylglycine, D-cyclopentylglycine, D-phenylalanine, D-2-thienylalanine, D-valine, D-2-furylglycine and D-3-furylglycine residue.
Claim 9
Dependent Claim
26 words
The compound according to claim 1, wherein C is selected from the group consisting of L-leucine, L-isoleucine, L-valine, L-norleucine and L-a-amino acid residue having aromatic moiety.
Claim 10
Dependent Claim
19 words
The compound according to claim 8, wherein C is selected from the group consisting of L-leucine, L-phenylalanine and L-tryptophan.
Claim 11
Dependent Claim
21 words
The compound according to claim 1, wherein D is D-tryptophan, or a derivative thereof, D-1-naphthylalanine, D-2-naphthylalanine, D-benzothienylalanine, D-4-bisphenylalanine and D-pentamethylphenylalanine residue.
Claim 12
Dependent Claim
29 words
The compound according to claim 10, wherein the derivative of tryptophan is selected from the group consisiting of D-N in- methyltryptophan, D-N in- formyltryptophan and D-N in- acetyltryptophan residue.
Claim 13
Dependent Claim
60 words
The compound according to claim 1, wherein A is D-aspartic acid residue; X is tryptophan, L-(β-4-phenylpiperazine amide)aspartic acid, L(N δ -phenylacetyl)ornithine, L-(N 4 [indol-3-yl]ethyl)ornithine, L-(4-benzyloxy)proline, L-(N 5- benzyl)glutamine or L-(N δ -[indol-3-yl]acetyl)asparagine residue; Y is L-leucine, L-aspartic acid, L-O-benzylserine, tryptophan, serine or proline residue; B is D-leucine, D-2-thienylglycine or D-3-thienylglycine residue; C is L-leucine residue; and D is D-tryptophan residue.
Claim 14
Dependent Claim
9 words
A compound according to claim 1, selected from: and
Claim 15
Dependent Claim
26 words
A pharmaceutical composition comprising the peptide claimed in claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient in a receptor antagonist effective amount.
Claim 16
Dependent Claim
26 words
The pharmaceutical composition claimed in claim 14 , which comprises the peptide of claim 1 or a pharmaceutically acceptable salt thereof in an endothelin receptor amount.
Claim 17
Dependent Claim
27 words
The pharmaceutical composition claimed in claim 14 , which comprises the peptide of claim 1 or a pharmaceutically acceptable salt thereof in an NK2 receptor antagonist amount.
Claim 18
Dependent Claim
93 words
A method of preparing the compound according to claim 1 or a salt thereof, which comprises condensing a starting material having a reactive carboxyl group corresponding to one of two kinds of fragments which are separated at any position of its peptide bond of the desired peptide with a starting material having a reactive amino group corresponding to the other fragment, subsequently eliminating protective groups of the C-terminal a-carboxyl group and the N-terminal a-amino group of the resulting compound concurrently or stepwise, thereafter conducting intramolecular condensation of both to obtain a cyclic compound.
Claim 19
Dependent Claim
23 words
Use of the compound according to claim 1 or the pharmaceutically acceptable salt thereof for manufacturing a medicament for an endothelin receptor antagonist.
Claim 20
Dependent Claim
23 words
Use of the compound according to claim 1 or the pharmaceutically acceptable salt thereof for manufacturing a medicament for an NK2 receptor antagonist.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.